Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Earnings for Ascendis Pharma A/S (ASND)
Earnings in 2023 (TTM): $-474,144,000
According to Ascendis Pharma A/S's latest financial reports the company's current earnings (TTM) are $-474,144,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ascendis Pharma A/S
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-474,144,000 | $-481,447,000 |
| 2022 | $-577,817,000 | $-583,194,000 |
| 2021 | $-383,944,000 | $-383,577,000 |
| 2020 | $-419,174,000 | $-418,955,000 |
| 2019 | $-218,250,000 | $-218,016,000 |
| 2018 | $-130,491,000 | $-130,097,000 |
| 2017 | $-124,374,000 | $-123,897,000 |
| 2016 | $-68,732,000 | $-68,505,000 |
| 2015 | $-33,574,000 | $-32,922,000 |
| 2014 | $-10,340,000 | $-9,658,000 |
| 2013 | $4.71 M | $4.08 M |
| 2012 | $1.29 M | $1.25 M |